Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/23558
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLeal, Jose Luis-
dc.contributor.authorPeters, Geoffrey-
dc.contributor.authorSzaumkessel, Marcin-
dc.contributor.authorLeong, Trishe Y-M-
dc.contributor.authorAsadi, Khashayar-
dc.contributor.authorRivalland, Gareth-
dc.contributor.authorDo, Hongdo-
dc.contributor.authorSenko, Clare-
dc.contributor.authorMitchell, Paul L R-
dc.contributor.authorQuing, Chai Zi-
dc.contributor.authorDobrovic, Alexander-
dc.contributor.authorThapa, Bibhusal-
dc.contributor.authorJohn, Thomas-
dc.date2020-05-24-
dc.date.accessioned2020-06-18T00:24:58Z-
dc.date.available2020-06-18T00:24:58Z-
dc.date.issued2020-08-
dc.identifier.citationLung Cancer 2020; 146: 154-159en
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/23558-
dc.description.abstractGene rearrangements involving NTRK1, NTRK2, NTRK3, ROS1 and ALK have been identified in many types of cancer, including non-small cell lung cancer (NSCLC). Data in malignant pleural mesothelioma (MPM), lung neuroendocrine tumors (NETs) and small-cell lung cancer (SCLC) are lacking. Given the activity of NTRK, ROS-1 and ALK inhibitors in tumors harboring gene fusions, we sought to explore such rearrangements in these less common tumors in addition to NSCLC. Archival tumor tissue from patients with MPM, lung NETs, SCLC and NSCLC were used to create tissue microarrays. Immunohistochemistry (IHC) was performed using a cocktail of antibodies against TRK, ROS1 and ALK. IHC positive samples underwent RNA sequencing using the ArcherDX FusionPlex CTL diagnostic assay. Clinical data were obtained through retrospective chart review. We performed IHC on 1116 samples: 335 MPMs, 522 NSCLCs, 105 SCLCs and 154 lung NETs. There were 23 IHC positive cases (2.1%) including eight MPMs (2.4%), eight NETs (5.2%), five SCLC (4.8%) and two NSCLC (0.4%). The following fusions were detected: one MPM with an NTRK ex10-TPM3 ex8, another MPM with an ALK ex20-EML4ex13, one lung intermediate-grade NET (atypical carcinoid) with an ALK ex20-EML4 ex6/intron6, and two NSCLCs with an ALK ex20-EML4 ex6/intron6 rearrangement. None of the patients received targeted treatment. To our knowledge, we report for the first time NTRK and ALK rearrangements in a small subset of MPM. An ALK rearrangement was also detected in lung intermediate-grade NET (or atypical carcinoid). Our data suggest that IHC could be a useful screening test in such patients to ensure that all therapeutic strategies including targeted therapy are utilized.en
dc.language.isoeng-
dc.subjectALKen
dc.subjectLung neuroendocrine tumorsen
dc.subjectMesotheliomaen
dc.subjectNTRKen
dc.subjectNon-small cell lung cancer.en
dc.titleNTRK and ALK rearrangements in malignant pleural mesothelioma, pulmonary neuroendocrine tumours and non-small cell lung cancer.en
dc.typeJournal Articleen
dc.identifier.journaltitleLung Canceren
dc.identifier.affiliationDepartment of Cardiothoracic Vascular Surgery, Manmohan Cardiothoracic Vascular and Transplant Centre, Kathmandu, Nepalen
dc.identifier.affiliationOlivia Newton-John Cancer Wellness and Research Centre, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationDepartment of Medical Oncology, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationPeter MacCallum Cancer Centre, Melbourne, Victoria, Australiaen
dc.identifier.affiliationDepartment of Surgery, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationDepartment of Anatomical Pathology, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationOlivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationDepartment of Anatomical Pathology, St Vincent's Hospital, Fitzroy, Victoria, Australiaen
dc.identifier.affiliationANU Medical School, Australian National University, Australian Capital Territory, Australiaen
dc.identifier.affiliationDepartment of Medical Oncology, The Canberra Hospital, Australian Capital Territory, Australiaen
dc.identifier.doi10.1016/j.lungcan.2020.05.019en
dc.type.contentTexten
dc.identifier.orcid0000-0003-3399-5342en
dc.identifier.orcid0000-0003-3414-112Xen
dc.identifier.pubmedid32540558-
dc.type.austinJournal Article-
local.name.researcherAsadi, Khashayar
item.openairetypeJournal Article-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
crisitem.author.deptPathology-
crisitem.author.deptMedical Oncology-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
crisitem.author.deptSurgery (University of Melbourne)-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
crisitem.author.deptThoracic Surgery-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

36
checked on Feb 29, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.